Brief: Pharnext: Financing Agreement With Néovacs For EUR 20.7 Mln Net To Further Develop PXT3003
03/10/2022 17:12
Oct 3 (Reuters) - Pharnext SA PHARN.PA :
* PHARNEXT EXECUTES A FINANCING AGREEMENT WITH NÉOVACS FOR
EUR
20.7 MILLION NET TO FURTHER DEVELOP PXT3003 FOR
CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
* CUMULATIVE FINANCING RESULTING FROM THESE AGREEMENTS
BRINGS A
TOTAL POTENTIALLY AVAILABLE NET AMOUNT OF APPROXIMATELY EUR 46.7
MILLION
* SUBJECT TO EACH PARTY'S SATISFYING ITS OBLIGATIONS,
CONSIDERS IT
WOULD BE ABLE TO FINANCE ITS OPERATIONS, PREMIER TRIAL UNTIL Q1
2024
Source text for Eikon: ID:nEQ2n0MB7a
Further company coverage: PHARN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development